Company / Working Capital
IOVANCE BIOTHERAPEUTICS, INC. Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$304.3M
FY2025
5-year range
$197.5M / $418.8M
FY2021-FY2025
Trend
-9.1%
vs FY2024
Sector context
#138 of 213
Health Care
What the data says
At $304M, IOVANCE BIOTHERAPEUTICS, INC.'s working capital ranks #138 of 213 in the Health Care sector. Working Capital has fluctuated over the past 10 years, ranging from $140M in FY2017 to $581M in FY2020.
Based on SEC 10-K filings.
$304M in FY2025 with a 5-year CAGR of -12.1%.
Improved from $198M to $304M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -7.7%
- 5-Year CAGR
- -12.1%
- 10-Year CAGR
- -
Sector benchmark
#138 of 213 in Health CareTop 65% of 213This company $304.3M Sector average $934.6M
▼
-67.4% below sector average
Key checks
Key Insights
- 5-year CAGR of -12.1%, indicating a declining trend.
- In FY2025, working capital decreased 9.1% year-over-year.
- Ranks #138 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.05 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $304.3M | -9.1% |
| FY2024 | $334.7M | +69.4% |
| FY2023 | $197.5M | -49.0% |
| FY2022 | $387.6M | -7.4% |
| FY2021 | $418.8M | -28.0% |
| FY2020 | $581.2M | +109.5% |
| FY2019 | $277.4M | -39.8% |
| FY2018 | $461.0M | +230.0% |
| FY2017 | $139.7M | -15.1% |
| FY2016 | $164.5M | +60.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026